Document is current
Any future updates will be listed below
-
Authors
Drost, Felix https://orcid.org/0000-0002-2600-4048
An, Yang https://orcid.org/0000-0003-1225-3534
Bonafonte-Pardàs, Irene
Dratva, Lisa M. https://orcid.org/0000-0002-2873-6787
Lindeboom, Rik G. H. https://orcid.org/0000-0002-3660-504X
Haniffa, Muzlifah https://orcid.org/0000-0002-3927-2084
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
Theis, Fabian https://orcid.org/0000-0002-2419-1943
Lotfollahi, Mohammad https://orcid.org/0000-0001-6858-7985
Schubert, Benjamin https://orcid.org/0000-0003-3412-1102
- License Information
-
More Information
Article History
Received: 10 October 2023
Accepted: 23 May 2024
First Online: 3 July 2024
Competing interests
: M.L. consults Santa Anna Bio, owns interests in Relation Therapeutics and is a scientific cofounder and part-time employee at AIVIVO. F.T. reports receiving consulting fees from Roche Diagnostics GmbH and Cellarity Inc., and an ownership interest in Cellarity, Inc. Y.A. acknowledges financial support by JURA Bio, Inc. S.A.T is on the advisory board for Cell Genomics. L.M.D., R.G.H.L. and S.A.T. are inventors on a filed patent that is related to the detection and application of activated T cells. In the past 3 years, S.A.T. has received remuneration for Scientific Advisory Board Membership from Sanofi, GlaxoSmithKline, Foresite Labs and Qiagen. S.A.T. is a co-founder and holds equity in Transition Bio and Ensocell. From 8 January 2024, S.A.T. is a part-time employee of GlaxoSmithKline. The remaining authors declare no competing interests.
